ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data

OBJECTIVES: ALK inhibitors (ALKi) are the standard-of-care treatment for metastatic ALK-rearranged non-small cell lung cancer (NSCLC) in the first- and second-line setting. We conducted a real-world multi-institutional analysis, aiming to compare the efficacy of third-line ALKi versus chemotherapy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Moskovitz, Mor, Dudnik, Elizabeth, Shamai, Sivan, Rotenberg, Yakir, Popovich-Hadari, Noa, Wollner, Mira, Zer, Alona, Gottfried, Maya, Mishaeli, Moshe, Rosenberg, Shoshana Keren, Onn, Amir, Merimsky, Ofer, Urban, Damien, Peled, Nir, Maimon, Natalie, Bar, Jair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842297/
https://www.ncbi.nlm.nih.gov/pubmed/35305096
http://dx.doi.org/10.1093/oncolo/oyab005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842297/
https://www.ncbi.nlm.nih.gov/pubmed/35305096
http://dx.doi.org/10.1093/oncolo/oyab005

Ejemplares similares